| abstract |
The present invention relates to a cardiac targeting agent comprising tannic acid, which, by TANNylating a heart disease therapeutic agent to be delivered to the heart, provides the heart disease therapeutic agent with the ability to bind to the cardiac myocardium, thus enabling cardiac targeting and accumulation of the therapeutic agent, wherein the therapeutic agent can be targeted to the heart with high efficiency even via non-invasive intravenous administration alone, unlike conventional invasive methods used to target therapeutic agents to the heart. |